<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847494</url>
  </required_header>
  <id_info>
    <org_study_id>2016-6342</org_study_id>
    <nct_id>NCT02847494</nct_id>
  </id_info>
  <brief_title>Corticosteroids for Acute Migraine in the Emergency Department</brief_title>
  <official_title>Corticosteroids for Acute Migraine. An ED-based, Randomized, Comparative Effectiveness Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an emergency department based randomized trial in which we compare two different
      treatment for migraine headache. The goal is to decrease the number of headache days during
      the week after ED discharge.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">September 30, 2017</completion_date>
  <primary_completion_date type="Actual">September 21, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Days as Self-reported by Participants</measure>
    <time_frame>7 days after discharge from emergency department</time_frame>
    <description>At the seven day follow-up, participants will be asked by phone how many days they experienced headaches since being discharged.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Sustained Headache Freedom</measure>
    <time_frame>7 days after discharge from emergency department</time_frame>
    <description>Sustained headache freedom is defined as achieving a headache intensity = none within two hours of treatment and maintaining this level, without requiring additional headache medication, for 7 days following discharge from the Emergency Department. Participants will be asked by phone how number of days they experienced headaches during the week after discharge from the emergency department. Reported values are participants who experienced no headaches at all during the 7 days immediately following discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Preference as Assessed by Self-report</measure>
    <time_frame>7 days after discharge from emergency department</time_frame>
    <description>Participants will be asked, by phone, if they would want the same medication during a subsequent visit to the emergency department. Reported values indicate participants who responded &quot;yes&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10mg IV+ dexamethasone 10mg IM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metoclopramide</intervention_name>
    <description>metoclopramide 10mg intravenous infusion over 15 minutes</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>dexamethasone 10mg intramuscular injection</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone acetate</intervention_name>
    <description>methylprednislone acetate 160mg intramuscular injection</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Migraine without aura criteria (International Classification of Headache Disorders 3B
             )

          -  Headache rated as moderate or severe in intensity

        Exclusion Criteria:

          -  Concern for secondary cause of headache

          -  Contra-indications to investigational medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin W Friedman, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center--Einstein</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center-Moses</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <results_first_submitted>December 18, 2018</results_first_submitted>
  <results_first_submitted_qc>December 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02847494/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Metoclopramide 10mg IV+ dexamethasone 10mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
Dexamethasone: dexamethasone 10mg intramuscular injection</description>
        </group>
        <group group_id="P2">
          <title>Experimental</title>
          <description>Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
methylprednisolone acetate: methylprednislone acetate 160mg intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Metoclopramide 10mg IV+ dexamethasone 10mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
Dexamethasone: dexamethasone 10mg intramuscular injection</description>
        </group>
        <group group_id="B2">
          <title>Experimental</title>
          <description>Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
methylprednisolone acetate: methylprednislone acetate 160mg intramuscular injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="13"/>
                    <measurement group_id="B2" value="39" spread="16"/>
                    <measurement group_id="B3" value="38" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of headache</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="109"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="24" upper_limit="96"/>
                    <measurement group_id="B2" value="72" lower_limit="24" upper_limit="120"/>
                    <measurement group_id="B3" value="72" lower_limit="24" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Headache Days as Self-reported by Participants</title>
        <description>At the seven day follow-up, participants will be asked by phone how many days they experienced headaches since being discharged.</description>
        <time_frame>7 days after discharge from emergency department</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Metoclopramide 10mg IV+ dexamethasone 10mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
Dexamethasone: dexamethasone 10mg intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
methylprednisolone acetate: methylprednislone acetate 160mg intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Days as Self-reported by Participants</title>
          <description>At the seven day follow-up, participants will be asked by phone how many days they experienced headaches since being discharged.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.5" upper_limit="3.5"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.8" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Sustained Headache Freedom</title>
        <description>Sustained headache freedom is defined as achieving a headache intensity = none within two hours of treatment and maintaining this level, without requiring additional headache medication, for 7 days following discharge from the Emergency Department. Participants will be asked by phone how number of days they experienced headaches during the week after discharge from the emergency department. Reported values are participants who experienced no headaches at all during the 7 days immediately following discharge.</description>
        <time_frame>7 days after discharge from emergency department</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Metoclopramide 10mg IV+ dexamethasone 10mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
Dexamethasone: dexamethasone 10mg intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
methylprednisolone acetate: methylprednislone acetate 160mg intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Headache Freedom</title>
          <description>Sustained headache freedom is defined as achieving a headache intensity = none within two hours of treatment and maintaining this level, without requiring additional headache medication, for 7 days following discharge from the Emergency Department. Participants will be asked by phone how number of days they experienced headaches during the week after discharge from the emergency department. Reported values are participants who experienced no headaches at all during the 7 days immediately following discharge.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Preference as Assessed by Self-report</title>
        <description>Participants will be asked, by phone, if they would want the same medication during a subsequent visit to the emergency department. Reported values indicate participants who responded &quot;yes&quot;.</description>
        <time_frame>7 days after discharge from emergency department</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Metoclopramide 10mg IV+ dexamethasone 10mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
Dexamethasone: dexamethasone 10mg intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
methylprednisolone acetate: methylprednislone acetate 160mg intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Preference as Assessed by Self-report</title>
          <description>Participants will be asked, by phone, if they would want the same medication during a subsequent visit to the emergency department. Reported values indicate participants who responded &quot;yes&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Metoclopramide 10mg IV+ dexamethasone 10mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
Dexamethasone: dexamethasone 10mg intramuscular injection</description>
        </group>
        <group group_id="E2">
          <title>Experimental</title>
          <description>Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
metoclopramide: metoclopramide 10mg intravenous infusion over 15 minutes
methylprednisolone acetate: methylprednislone acetate 160mg intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin W. Friedman, MD</name_or_title>
      <organization>Montefiore Health</organization>
      <phone>17189206626</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

